MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Sitges, España
Joined March 2017
- Tweets4.5K
- Following610
- Followers3.6K
- Likes10.4K
Pinned Tweet
Proud to support @RManochakian in his candidacy for the #ASCO Nominating Committee! An outstanding colleague and a dedicated leader with a strong commitment to our oncology community. Wishing you every success, Rami! 👏
#Voting for @ASCO Election is now open.
I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.
Visit asco.org/election to learn more about the candidates & place your vote!
So much anger and sadness. This should never happen. My heart goes out to the victims and their families.
Devastating news —we were just #ESMO26 in Madrid. 42,000 people. I hope all our colleagues are safe going back from @myESMO ….
Prayers for the victims and families.
bbc.com/news/live/cv1j309d4g…
Excellent discussion by @DrJNaidoo at presidential #ESMO26 on non-inferiority trials and treatment de-escalation in oncology. Less treatment w|out compromising efficacy? The challenges: defining acceptable margins, selecting right patients, ensuring clinically meaningful outcomes
Bringing people together from around the world! 🌍 The spirit of the entire ESMO community. #ESMO26 💚
Another negative phase III trial in pretreated NSCLC! ❌ SigVie-002 sigvotatug vedotin vs docetaxel failed to meet its primary OS endpoint in non-squamous NSCLC. @peters_solange. The challenge of beating docetaxel with ADCs in 2L continues! #ESMO26 #LungCancer
Just a reminder of the phase III trial landscape and outcomes reported so far with ADC-based combinations in first-line non-oncogene-addicted NSCLC.
OptiTROP-Lung06 now @NEJM after #ESMO26 presentation showing Sac-TMT (TROP2 ADC) + pembro superior to standard chemotherapy + pembro. #ESMOAmbassadors @myESMO
nejm.org/doi/full/10.1056/NE…
Impressive results Academic III PERSEE #ESMO26 @Annals_Oncology First positive random trial adding chemo to pembro in PD-L1 ≥50% NSCLC:
🔹 PFS: 16.1 vs 6.9 mo HR 0.56
🔹 OS: 50.2 vs 29.9 mo HR 0.77, NS
🔹 G≥3 TRAEs: 54% vs 19%
Outstanding discussion Prof. Levy
@benlevylungdoc.
Proud to be part of the Women for Oncology (W4O) session at #ESMO26 peters_solange @Piuchagarrido @ElinardouHelena highlighting barriers and opportunities for women in oncology. Inspiring call to challenge inequalities, break down barriers and empower women to thrive and lead!!!
Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated that we might finally be bending gravity. Today, that vision is becoming a reality!!!!!!👏👏👏👏👏
Impressive results from phase III DeLLphi-305 at #ESMO26 @sands_jacob: Adding tarlatamab to durvalumab maintenance in ES-SCLC 1-y OS nearly 80%!!!
🔹 OS: 21.1 vs 12.7 mo (HR 0.42)
🔹 PFS: 7.4 vs 1.9 mo (HR 0.34)
A standing ovation!” 👏👏👏👏A major step forward for SCLC! @NEJM
Looking forward to the #ESMO26 Presidential Symposium! Exciting DeLLphi-305 data in ES-SCLC, presented by @JacobSandsMD, followed by what promises to be an insightful discussion from Dr. Stephen Liu @StephenVLiu Auditorium packed! #ESMO26
Join us today at the #ESMO26 Opening Session with @FAndreMD to celebrate our outstanding awardees: Professors Rebecca Fitzgerald, Dan Landau, Antoni Ribas and Pilar Garrido! Congratulations to all! 👏
📍 Alicante Auditorium, Hall 6
🕦 11:30–13:00
See you there!
Discover “Targeted cancer #immunotherapy with PD-1 blockade” with Antoni Ribas, recipient of the 2026 ESMO Lifetime Achievement Award, at the #ESMO26 Congress Opening Session.
🔗 ow.ly/pStp50ZXThk
First day at #ESMO26!
Exceptional international faculty @EnriquetaFelip, Dr. Antonio Passaro, @MARIANOPROVENCI and Maria Karen, exploring the many facets of NSCLC management, always keeping patients’ preferences at the heart of decision-making. Full house at #ESMO26!
How important it is to hear the surgeon’s perspective on defining resectability and its challenges! Excellent insights from Dr. Stiles @BrendonStilesMD at the Expert Meeting on Non-Metastatic NSCLC. #Madrid @peters_solange @FedericoCappuz1
Me uno a los agradecimientos. ¡Felicidades, un año más, por la excelente organización y, sobre todo, por la magnífica acogida! 👏👏
⭐️ Siempre es un placer compartir con los compañeros gallegos esta jornada lleva de información, afable, y enriquecedora. Agradecer el cariño y la entrega que ponen los organizadores y las constantes mejoras que introducen cada año @mlazqui Sergio Vázquez. Deseando competir el año que viene por la nécora de plata 🦀 🤣
There's a new version of this post
4
210
Looking forward to this new Meet the Professor in Thoracic Tumors virtual session! It will be a pleasure to have professor @peters_solange sharing the latest developments in thoracic oncology. Together with @EnriquetaFelip, we are delighted to have you join us on September 22!
LAST CALL 💻 Meet the Professor in Thoracic Tumors: @peters_solange
On September 22, Dr. Solange Peters will lead a new virtual session focused on the latest developments in thoracic tumors.
🩺 Scientific coordination: Dr. @EnriquetaFelip and Dr. @NReguart
📅 September 22 · Virtual
Programme and registration ⤵️
tacticsmd.net/actividad/vii-…
#ThoracicTumors #LungCancer #Oncology #MedicalEducation
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetrexed in HER2-mutant NSCLC: 14.3 vs 8.3 mo | HR 0.63 (95% CI 0.50–0.79), P<0.0001. IA No OS benefit. Of note considerable ILD (overall 20.8%, 2% Gr 5).@JuliaRotow
#HER2 #NSCLC #LCSM
